Literature DB >> 29549162

A Novel TGFβ Trap Blocks Chemotherapeutics-Induced TGFβ1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers.

Haiyan Zhu1,2, Xiang Gu2, Lu Xia2,3, You Zhou2, Hakim Bouamar2, Junhua Yang2, Xiaofei Ding2, Christian Zwieb4, Jianan Zhang1, Andrew P Hinck4, Lu-Zhe Sun5,2, Xueqiong Zhu5.   

Abstract

Purpose: We investigated the mechanisms of how TGFβ pathway is activated by chemotherapeutics and whether a novel TGFβ trap called RER can block chemotherapeutics-induced TGFβ pathway activation and enhance their antitumor activity in gynecologic cancer.Patients and
Methods: An unbiased bioinformatic analysis of differentially expressed genes in 31 ovarian cases due to chemotherapy was used to identify altered master regulators. Phosphorylated Smad2 was determined in 30 paired cervical cancer using IHC. Furthermore, the effects of chemotherapeutics on TGFβ signaling and function, and the effects of RER on chemotherapy-induced TGFβ signaling were determined in gynecologic cancer cells.
Results: Chemotherapy-induced transcriptome alteration in ovarian cancer was significantly associated with TGFβ signaling activation. Chemotherapy was found to activate TGFβ signaling as indicated by phosphorylated Smad2 in paired cervical tumor samples (pre- and post-chemotherapy). Similar to TGFβ1, chemotherapeutics were found to stimulate Smad2/3 phosphorylation, cell migration, and markers related to epithelial-mesenchymal transition (EMT) and cancer stem cells (CSC). These TGFβ-like effects were due to the stimulation of TGFβ1 expression and secretion, and could all be abrogated by TGFβ inhibitors including a novel TGFβ trap protein called RER both in vitro and in vivo Importantly, combination treatment with RER and cisplatin showed a higher tumor inhibitory activity than either agent alone in a xenograft model of ovarian cancer.Conclusions: Chemotherapeutics can stimulate TGFβ1 production and consequently enhance TGFβ signaling, EMT, and CSC features resulting in reduced chemo-sensitivity. Combination therapy with a TGFβ inhibitor should alleviate this unintended side effect of chemotherapeutics and enhance their therapeutic efficacy. Clin Cancer Res; 24(12); 2780-93. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29549162      PMCID: PMC6004245          DOI: 10.1158/1078-0432.CCR-17-3112

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

Authors:  Juswinder Singh; Claudio E Chuaqui; P Ann Boriack-Sjodin; Wen Cherng Lee; Timothy Pontz; Michael J Corbley; H-Kam Cheung; Robert M Arduini; Jonathan N Mead; Miki N Newman; James L Papadatos; Scott Bowes; Serene Josiah; Leona E Ling
Journal:  Bioorg Med Chem Lett       Date:  2003-12-15       Impact factor: 2.823

2.  Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.

Authors:  Mengxian Zhang; Susanne Kleber; Manuel Röhrich; Carmen Timke; Na Han; Jochen Tuettenberg; Ana Martin-Villalba; Juergen Debus; Peter Peschke; Ute Wirkner; Michael Lahn; Peter E Huber
Journal:  Cancer Res       Date:  2011-10-17       Impact factor: 12.701

3.  Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy.

Authors:  LanYing Jin; Qi Shen; Shengdi Ding; Wenxiao Jiang; Lingling Jiang; Xueqiong Zhu
Journal:  Gynecol Oncol       Date:  2012-04-06       Impact factor: 5.482

4.  Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.

Authors:  T Mizuno; N Suzuki; H Makino; T Furui; E Morii; H Aoki; T Kunisada; M Yano; S Kuji; Y Hirashima; A Arakawa; S Nishio; K Ushijima; K Ito; Y Itani; K Morishige
Journal:  Gynecol Oncol       Date:  2014-12-23       Impact factor: 5.482

5.  Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.

Authors:  Abhik Bandyopadhyay; Long Wang; Joseph Agyin; Yuping Tang; Shu Lin; I-Tien Yeh; Keya De; Lu-Zhe Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

6.  Immunohistochemical expression of RAGE and its ligand (S100A9) in cervical lesions.

Authors:  Xuejie Zhu; Lanying Jin; Shuangwei Zou; Qi Shen; Wenxiao Jiang; Wenjing Lin; Xueqiong Zhu
Journal:  Cell Biochem Biophys       Date:  2013-07       Impact factor: 2.194

Review 7.  Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.

Authors:  Caitlin D May; Nathalie Sphyris; Kurt W Evans; Steven J Werden; Wenjun Guo; Sendurai A Mani
Journal:  Breast Cancer Res       Date:  2011-02-08       Impact factor: 6.466

8.  Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.

Authors:  Jianqun Liao; Feng Qian; Nana Tchabo; Paulette Mhawech-Fauceglia; Amy Beck; Zikun Qian; Xinhui Wang; Wendy J Huss; Shashikant B Lele; Carl D Morrison; Kunle Odunsi
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

9.  ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.

Authors:  Takafumi Kuroda; Yoshihiko Hirohashi; Toshihiko Torigoe; Kazuyo Yasuda; Akari Takahashi; Hiroko Asanuma; Rena Morita; Tasuku Mariya; Takuya Asano; Masahito Mizuuchi; Tsuyoshi Saito; Noriyuki Sato
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

View more
  21 in total

1.  Targeting all transforming growth factor-β isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer.

Authors:  Kazuki Takahashi; Yuichi Akatsu; Katarzyna A Podyma-Inoue; Takehisa Matsumoto; Hitomi Takahashi; Yasuhiro Yoshimatsu; Daizo Koinuma; Mikako Shirouzu; Kohei Miyazono; Tetsuro Watabe
Journal:  J Biol Chem       Date:  2020-07-06       Impact factor: 5.157

Review 2.  TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects.

Authors:  Kojo Agyemang; Allan M Johansen; Grayson W Barker; Michael J Pennison; Kimberly Sheffield; Hugo Jimenez; Carl Blackman; Sambad Sharma; Patrick A Fordjour; Ravi Singh; Katherine L Cook; Hui-Kuan Lin; Wei Zhang; Hui-Wen Lo; Kounosuke Watabe; Peiqing Sun; Carl D Langefeld; Boris Pasche
Journal:  NPJ Breast Cancer       Date:  2022-07-19

Review 3.  Exploiting Canonical TGFβ Signaling in Cancer Treatment.

Authors:  Qi Liu; Genwen Chen; Jade Moore; Ines Guix; Dimitris Placantonakis; Mary Helen Barcellos-Hoff
Journal:  Mol Cancer Ther       Date:  2021-10-20       Impact factor: 6.009

4.  Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy.

Authors:  Nils Ludwig; Łukasz Wieteska; Cynthia S Hinck; Saigopalakrishna S Yerneni; Juliana H Azambuja; Richard J Bauer; Torsten E Reichert; Andrew P Hinck; Theresa L Whiteside
Journal:  Mol Cancer Ther       Date:  2021-04-13       Impact factor: 6.261

5.  Reverse of microtubule-directed chemotherapeutic drugs resistance induced by cancer-associated fibroblasts in breast cancer.

Authors:  Xuebo Li; Qiang Li; Xiuli Yu; Haitao Li; Guoqiang Huang
Journal:  Onco Targets Ther       Date:  2019-09-27       Impact factor: 4.147

Review 6.  A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment.

Authors:  Linh Khanh Huynh; Christopher John Hipolito; Peter Ten Dijke
Journal:  Biomolecules       Date:  2019-11-17

Review 7.  TGFβ-Directed Therapeutics: 2020.

Authors:  Beverly A Teicher
Journal:  Pharmacol Ther       Date:  2020-08-21       Impact factor: 12.310

Review 8.  On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?

Authors:  Adilson Fonseca Teixeira; Peter Ten Dijke; Hong-Jian Zhu
Journal:  Front Cell Dev Biol       Date:  2020-07-08

Review 9.  Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity.

Authors:  Stéphane Terry; Rania Faouzi Zaarour; Goutham Hassan Venkatesh; Amirtharaj Francis; Walid El-Sayed; Stéphanie Buart; Pamela Bravo; Jérome Thiery; Salem Chouaib
Journal:  Int J Mol Sci       Date:  2018-10-06       Impact factor: 5.923

10.  USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2.

Authors:  Ning Dou; Qingqing Hu; Li Li; Qiong Wu; Yandong Li; Yong Gao
Journal:  Int J Biol Sci       Date:  2020-03-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.